HUE030737T2 - Modafinil kokainfüggõk kezelésében történõ alkalmazásra - Google Patents
Modafinil kokainfüggõk kezelésében történõ alkalmazásra Download PDFInfo
- Publication number
- HUE030737T2 HUE030737T2 HUE13715263A HUE13715263A HUE030737T2 HU E030737 T2 HUE030737 T2 HU E030737T2 HU E13715263 A HUE13715263 A HU E13715263A HU E13715263 A HUE13715263 A HU E13715263A HU E030737 T2 HUE030737 T2 HU E030737T2
- Authority
- HU
- Hungary
- Prior art keywords
- cocaine
- treatment
- modafinil
- composition
- dissolution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (5)
- Szabadalma Igénypontok 1. S-niodaítml--alapü gyógyszerészed készítmény kokaminggók helyettesítő kezelésében tórtéuó alkalmazásra, azzal jellemezve, hogy az S~modafimli szuperkritikus folyadék technológiával kapjuk, az S-atodáfutil egy Inert hordozóban létrehozott granulátumok léiül el én abszorbeált,
- 2. Készítmény alkalmazásra az 1, igénypont szerint, azzal jellemezve, hogy a folyadék a 40;.
- 3. K-észltmény alkalmazásra az 1, vagy 2, igénypont szerint, azzal jellemezve, hogy a hordozó vízmentes laktöz.
- 4. Készítmény alkalmazásra az 1... vagy 2. igénypont szerint, azzal jellemezve, begy a hordozd marmit,
- 5. Készítmény a lka !tn ázásra az 1 -4 igénypontok bártnelyike szerint, azzal jellemezve, hogy a készítmény tabletta formájú, 4 Kiszitmény alkalmazásra az 5, igénypont szerint, azzal jellemezve, hogy a tabletta 25-200 mg S-modaiímit tartalmaz- ?. Készítmény alkalmazásra a 6, igénypont szerint, azzal jellemezve, hogy a tabletta 50400 mg S-modafiniit tartalmaz.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1200581A FR2987267B1 (fr) | 2012-02-28 | 2012-02-28 | Application du modafinil dans le traitement de substitution des cacainomanes |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE030737T2 true HUE030737T2 (hu) | 2017-05-29 |
Family
ID=48083447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE13715263A HUE030737T2 (hu) | 2012-02-28 | 2013-02-25 | Modafinil kokainfüggõk kezelésében történõ alkalmazásra |
Country Status (33)
Country | Link |
---|---|
US (1) | US20150073055A1 (hu) |
EP (1) | EP2819655B1 (hu) |
JP (1) | JP6163169B2 (hu) |
KR (1) | KR101897855B1 (hu) |
CN (1) | CN104159575B (hu) |
AR (1) | AR090169A1 (hu) |
AU (1) | AU2013224831B2 (hu) |
BR (1) | BR112014020626A2 (hu) |
CA (1) | CA2863159C (hu) |
CL (1) | CL2014002203A1 (hu) |
CY (1) | CY1118166T1 (hu) |
DK (1) | DK2819655T3 (hu) |
EA (1) | EA025692B1 (hu) |
ES (1) | ES2593276T3 (hu) |
FR (1) | FR2987267B1 (hu) |
HR (1) | HRP20161165T1 (hu) |
HU (1) | HUE030737T2 (hu) |
IL (1) | IL234009B (hu) |
IN (1) | IN2014DN07831A (hu) |
LT (1) | LT2819655T (hu) |
MX (1) | MX348222B (hu) |
NZ (1) | NZ628009A (hu) |
PH (1) | PH12014501837A1 (hu) |
PL (1) | PL2819655T3 (hu) |
PT (1) | PT2819655T (hu) |
RS (1) | RS55238B1 (hu) |
SG (1) | SG11201405316WA (hu) |
SI (1) | SI2819655T1 (hu) |
SM (1) | SMT201600363B (hu) |
TW (1) | TWI626042B (hu) |
UA (1) | UA113301C2 (hu) |
WO (1) | WO2013128088A1 (hu) |
ZA (1) | ZA201405910B (hu) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105055404B (zh) * | 2015-08-19 | 2017-07-18 | 四川大学 | Hmgcs2抑制剂在制备治疗可卡因成瘾的药物中的用途 |
CN105055412B (zh) * | 2015-08-20 | 2018-06-19 | 四川大学 | Nampt抑制剂在制备治疗可卡因成瘾的药物中的用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618845A (en) * | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
FR2771004B1 (fr) | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
US20010034373A1 (en) | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
JP4593074B2 (ja) * | 2000-10-11 | 2010-12-08 | セフアロン・インコーポレーテツド | モダフィニル化合物含有組成物 |
US20040006532A1 (en) | 2001-03-20 | 2004-01-08 | David Lawrence | Network access risk management |
US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
US7093476B2 (en) | 2004-09-15 | 2006-08-22 | Ut-Battelle, Llc | Method for fabricating thin californium-containing radioactive source wires |
US20090123545A1 (en) * | 2005-07-21 | 2009-05-14 | Ron Eyal S | Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof |
EP2043623A4 (en) * | 2006-07-12 | 2013-03-20 | Elan Pharma Int Ltd | NANOPARTICLE FORMULATIONS OF MODAFINIL |
EP1980240A1 (en) * | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
US8173169B2 (en) * | 2007-07-11 | 2012-05-08 | Hikma Pharmaceuticals | Formulation and process for the preparation of modafinil |
-
2012
- 2012-02-28 FR FR1200581A patent/FR2987267B1/fr not_active Expired - Fee Related
-
2013
- 2013-02-25 NZ NZ628009A patent/NZ628009A/en not_active IP Right Cessation
- 2013-02-25 PL PL13715263T patent/PL2819655T3/pl unknown
- 2013-02-25 SG SG11201405316WA patent/SG11201405316WA/en unknown
- 2013-02-25 AU AU2013224831A patent/AU2013224831B2/en not_active Ceased
- 2013-02-25 LT LTEP13715263.3T patent/LT2819655T/lt unknown
- 2013-02-25 BR BR112014020626A patent/BR112014020626A2/pt not_active Application Discontinuation
- 2013-02-25 KR KR1020147023180A patent/KR101897855B1/ko active IP Right Grant
- 2013-02-25 IN IN7831DEN2014 patent/IN2014DN07831A/en unknown
- 2013-02-25 SI SI201330319A patent/SI2819655T1/sl unknown
- 2013-02-25 HU HUE13715263A patent/HUE030737T2/hu unknown
- 2013-02-25 US US14/381,896 patent/US20150073055A1/en not_active Abandoned
- 2013-02-25 PT PT137152633T patent/PT2819655T/pt unknown
- 2013-02-25 WO PCT/FR2013/000052 patent/WO2013128088A1/fr active Application Filing
- 2013-02-25 EP EP13715263.3A patent/EP2819655B1/fr active Active
- 2013-02-25 MX MX2014010237A patent/MX348222B/es active IP Right Grant
- 2013-02-25 ES ES13715263.3T patent/ES2593276T3/es active Active
- 2013-02-25 RS RS20160882A patent/RS55238B1/sr unknown
- 2013-02-25 DK DK13715263.3T patent/DK2819655T3/en active
- 2013-02-25 CA CA2863159A patent/CA2863159C/fr not_active Expired - Fee Related
- 2013-02-25 JP JP2014559270A patent/JP6163169B2/ja not_active Expired - Fee Related
- 2013-02-25 UA UAA201409664A patent/UA113301C2/uk unknown
- 2013-02-25 EA EA201400960A patent/EA025692B1/ru not_active IP Right Cessation
- 2013-02-25 CN CN201380011342.7A patent/CN104159575B/zh not_active Expired - Fee Related
- 2013-02-27 TW TW102106817A patent/TWI626042B/zh not_active IP Right Cessation
- 2013-02-27 AR ARP130100596A patent/AR090169A1/es unknown
-
2014
- 2014-08-07 IL IL234009A patent/IL234009B/en active IP Right Grant
- 2014-08-12 ZA ZA2014/05910A patent/ZA201405910B/en unknown
- 2014-08-14 PH PH12014501837A patent/PH12014501837A1/en unknown
- 2014-08-19 CL CL2014002203A patent/CL2014002203A1/es unknown
-
2016
- 2016-09-12 HR HRP20161165TT patent/HRP20161165T1/hr unknown
- 2016-10-12 SM SM201600363T patent/SMT201600363B/it unknown
- 2016-10-26 CY CY20161101079T patent/CY1118166T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI298020B (en) | Gabapentin analogues for sleep disorders | |
US9682069B2 (en) | Methods of treating Dravet syndrome | |
EP2892518B1 (en) | Compositions for treating parkinson's disease | |
PT2168585E (pt) | Composições farmacêuticas de um esteróide neuroactivo e as suas utilizações | |
Wilder et al. | Gastrointestinal tolerance of divalproex sodium | |
US11160758B2 (en) | Modified release formulations and uses thereof | |
Naeem et al. | Development and evaluation of controlled-release bilayer tablets containing microencapsulated tramadol and acetaminophen | |
EP1343495A2 (en) | Methods of treating anxiety disorders | |
CA3177277A1 (en) | Methods of use of t-type calcium channel modulators | |
CN104706604A (zh) | 一种吡仑帕奈冻干口崩片及其制备方法 | |
Wu et al. | Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats | |
HUE030737T2 (hu) | Modafinil kokainfüggõk kezelésében történõ alkalmazásra | |
CN111818913B (zh) | 含有拉科酰胺的药剂学缓释性组合物 | |
AU2018323443B2 (en) | Novel gamma aminobutyric acid type a receptor modulators for mood disorders | |
Aamir et al. | Production and stability evaluation of modified-release microparticles for the delivery of drug combinations | |
Waters | Treatment of advanced stage patients with Parkinson's disease | |
US20140142113A1 (en) | Method of treating inflammatory diseases using adenosine 2b receptor antagonists | |
Zhou et al. | Diazepam monotherapy or diazepam-ketamine dual therapy at different time points terminates seizures and reduces mortality in a status epilepticus animal model | |
CN101264329A (zh) | 一种用于消炎镇痛的药物组合物及其制备方法,用途 | |
Patsalos | The new generation of anti-epileptic drugs | |
EP2891491A1 (en) | Use of (r)-phenylpiracetam for the treatment of sleep disorders | |
Jabeen et al. | Studies on the effects of cyclodextrin polymer as a tableting aid on some selected analgesics | |
US20150025027A1 (en) | Combination of a Monosubstituted Sulfamate Derivate of the Natural Monosaccharide d-Fructose (Topiramate) with an Anti-Depressant from the Phenyl Ketone Class (Bupropion) for Treating Obesity and Plurimetabolic Syndromes | |
WO2023247665A1 (en) | Solid dispersions of psilocybin | |
US20170246194A1 (en) | Acetaminophen-Containing Analgesic Formulations With Reduced Hepatotoxicity |